Video: Sitting Down With… John Tomtishen - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Video: Sitting Down With… John Tomtishen

  • October 7, 2026

  • 1 min

Share

Clinical Scorecard: Video: Sitting Down With… John Tomtishen

At a Glance

CategoryDetail
ConditionCell therapy development
Key MechanismsThe interview discusses product characterization, chemistry, manufacturing and controls (CMC), scalability, and manufacturing strategies.
Target PopulationCell therapy developers
Care SettingCell therapy development and manufacturing

Key Highlights

  • John Tomtishen discusses changes he has witnessed across the cell therapy field.
  • He explains why developers should prioritize product characterization and CMC early in development.
  • The interview explores technologies and manufacturing strategies that could improve scalability.
  • Tomtishen shares his perspective on bringing the next generation of cell therapies to more patients.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          The interview concerns cell therapy development; no specific patient population or prescribing data are provided.

          The interview addresses development and manufacturing strategies for cell therapies, not specific treatment regimens.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Related Content